Lineage Cell Therapeutics, Inc.

DB:BT3 Stock Report

Market Cap: €155.6m

Lineage Cell Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Brian Culley

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage22.0%
CEO tenure6yrs
CEO ownership0.08%
Management average tenure3.7yrs
Board average tenure7.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Brian Culley's remuneration changed compared to Lineage Cell Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$24m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$3mUS$640k

-US$21m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$24m

Dec 31 2022US$2mUS$609k

-US$26m

Sep 30 2022n/an/a

-US$49m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$49m

Dec 31 2021US$3mUS$580k

-US$43m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$1mUS$552k

-US$21m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$59m

Dec 31 2019US$773kUS$536k

-US$12m

Sep 30 2019n/an/a

-US$52m

Jun 30 2019n/an/a

US$31m

Mar 31 2019n/an/a

US$57m

Dec 31 2018US$3mUS$155k

-US$46m

Compensation vs Market: Brian's total compensation ($USD2.91M) is above average for companies of similar size in the German market ($USD815.10K).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.

CEO

Brian Culley (53 yo)

6yrs

Tenure

US$2,905,130

Compensation

Mr. Brian M. Culley, M.A., M.B.A., served as Interim Chief Financial Officer, Principal Financial Officer at Lineage Cell Therapeutics, Inc. since July 8, 2022 until November 14, 2022. He served as Interim...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Culley
CEO, President & Director6yrsUS$2.91m0.082%
$ 127.6k
Jill Howe
CFO & Principal Financial and Accounting Officer1.8yrsUS$738.86k0.0056%
$ 8.7k
George Samuel
General Counsel & Company Secretary3yrsUS$1.21m0.0038%
$ 5.9k
Ioana Hone
Director of Investor Relationsno datano datano data
Charlotte Hubbert
Vice President of Corporate Developmentless than a yearno datano data
Brandi Roberts
Consultant3.7yrsUS$668.25kno data
William Annett
President & CEO of OncoCyte Corporationno dataUS$654.85kno data
Rami Skaliter
Chief Executive Officer of Cell Cure Neurosciencesno datano datano data
Alexandra Hernandez
Senior Director of Finance & Controller5yrsno datano data
Harold Waitz
Vice President of Regulatory Affairs & Quality Control29.7yrsUS$90.00kno data

3.7yrs

Average Tenure

53yo

Average Age

Experienced Management: BT3's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Culley
CEO, President & Director6yrsUS$2.91m0.082%
$ 127.6k
Don Bailey
Independent Director5.5yrsUS$130.50k0.084%
$ 130.8k
Angus Russell
Independent Director9.8yrsUS$138.00k0.046%
$ 72.1k
Anula Jayasuriya
Independent Director3.3yrsUS$128.00k0.0053%
$ 8.2k
Neal Bradsher
Independent Director15.2yrsUS$141.13k0.046%
$ 72.2k
Deborah Andrews
Independent Director10.4yrsUS$148.00k0.0083%
$ 12.8k
Michael Mulroy
Independent Chairman9.9yrsUS$151.13k0.14%
$ 213.0k
Dipti Amin
Independent Director3.4yrsUS$128.00k0.019%
$ 28.8k

7.9yrs

Average Tenure

63yo

Average Age

Experienced Board: BT3's board of directors are considered experienced (7.9 years average tenure).